Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
- Sponsor
- Asociación para Evitar la Ceguera en México
- Study ID
- NCT00347399
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Age Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 55 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab intravitreal injection — DRUG
- verteporfin photodynamic therapy — PROCEDURE
Study Details
The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.
Key Dates
- First listed
- Jul 4, 2006
- Start date
- Mar 31, 2006
- Status verified
- May 2024
- Primary completion
- Jun 30, 2006
- Completion
- Jun 30, 2007
Study Design
- Enrollment
- 25 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Visual acuity improvement at 6 months [ Time Frame: undefined ]
Related Studies
- Strategies for Improving Linkage-to-Care After Eye Disease ScreeningRecruiting · University of California, San Francisco · San Francisco, California
- Phase 1 Study of C.001 in Retinal DegenerationPHASE1 · Recruiting · Cellio Therapeutics Inc · Beverly Hills, California